What You Should Know:
– Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has announced an extended and expanded partnership with Bristol Myers Squibb (BMS).
– This collaboration aims to enhance clinical research processes, improve patient outcomes, and foster advancements in personalized healthcare.
Medidata and Bristol Myers Squibb Strengthen Partnership to Advance Clinical Research and Personalized Healthcare
As part of the agreement, Bristol Myers Squibb will continue utilizing the Medidata Platform while exploring additional capabilities within Medidata’s suite of products. These include:
– AI and advanced analytics to derive deeper insights from clinical trial data.
– Innovative data management solutions to streamline trial operations.
– The Medidata Clinical Data Studio, a newly launched tool designed to manage, monitor, and analyze clinical trials effectively.
This strategic partnership extension will enable Bristol Myers Squibb to strengthen engagement with trial sites and patients, optimize processes, and accelerate the delivery of life-changing therapies to those in need. By leveraging cutting-edge technology, both organizations aim to set new benchmarks in clinical research and personalized treatment development.
